New Zealand markets closed

ILMN Jun 2024 100.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.30000.0000 (0.00%)
At close: 01:19PM EDT
Full screen
Previous close2.3000
Open2.8500
Bid2.6000
Ask3.8000
Strike100.00
Expiry date2024-06-21
Day's range2.3000 - 2.8500
Contract rangeN/A
Volume86
Open interest198
  • PR Newswire

    Illumina's planned divestment of GRAIL approved by the European Commission

    Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan for GRAIL from the European Commission (EC).

  • Reuters

    UPDATE 2-EU approves Illumina's plan to divest cancer test maker Grail

    U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.

  • Reuters

    EU approves Illumina's plan to divest cancer test maker Grail

    BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ago. The company said it has reached an agreement with the European Commission on specific divestment options, but the method has not been finalised. Illumina founded Grail and spun it off in 2016, but re-acquired it in 2021 for $7.1 billion to enter the cancer early-detection market, before first securing EU regulatory approval.